ויאגרה 25 מג ישראל - עברית - Ministry of Health

ויאגרה 25 מג

pfizer pfe pharmaceuticals israel ltd - sildenafil as citrate - טבליות מצופות פילם - sildenafil as citrate 25 mg - sildenafil - sildenafil - treatment of erectile dysfunction.

ויאגרה 50 מג ישראל - עברית - Ministry of Health

ויאגרה 50 מג

pfizer pfe pharmaceuticals israel ltd - sildenafil as citrate - טבליות מצופות פילם - sildenafil as citrate 50 mg - sildenafil - sildenafil - treatment of erectile dysfunction.

ויאגרה 100 מג ישראל - עברית - Ministry of Health

ויאגרה 100 מג

pfizer pfe pharmaceuticals israel ltd - sildenafil as citrate - טבליות מצופות פילם - sildenafil as citrate 100 mg - sildenafil - sildenafil - treatment of erectile dysfunction.

סילדזן ישראל - עברית - Ministry of Health

סילדזן

taro international ltd, israel - sildenafil as citrate - תרחיף - sildenafil as citrate 25 mg / 1 ml - sildenafil

ניופוגן 30 MU בקבוקונים ישראל - עברית - Ministry of Health

ניופוגן 30 mu בקבוקונים

amgen europe b.v. - filgrastim - תמיסה להזרקה - filgrastim 30 mu/ml - filgrastim - filgrastim - - reduction in the duration and severity of neutropenia in patients treated with highly myelosuppressive chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes ).- reduction in the duration of neutropenia in patients undergoing high-dose cytotoxic chemotherapy followed by bone marrow transplantation. - in children or adults with severe congenital neutropenia cyclic neutropenia or idiopathic neutropenia a history of clinically important infections within the last 12 months and three documented episodes of neutropenia (with an anc< 5 x 1000000000) long-term administration of neupogen is indicated to increase neutrophil counts and to reduce infections. - neupogen is indicated for the mobilisation of autologous peripheral blood progenitor cells alone or following myelosuppressive chemotherapy and the mobilisation of peripheral blood progenitor cells in normal donors (allogeneic pbpc).

ניופוגן MU 48 מזרק מוכן לשימוש ישראל - עברית - Ministry of Health

ניופוגן mu 48 מזרק מוכן לשימוש

amgen europe b.v. - filgrastim - תמיסה להזרקה - filgrastim 48 mu / 0.5 ml - filgrastim - filgrastim - - reduction in the duration and severity of neutropenia in patients treated with highly myelosuppressive chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes ).- reduction in the duration of neutropenia in patients undergoing high-dose cytotoxic chemotherapy followed by bone marrow transplantation. - in children or adults with severe congenital neutropenia cyclic neutropenia or idiopathic neutropenia a history of clinically important infections within the last 12 months and three documented episodes of neutropenia (with an anc< 5 x 1000000000) long-term administration of neupogen is indicated to increase neutrophil counts and to reduce infections. - neupogen is indicated for the mobilisation of autologous peripheral blood progenitor cells alone or following myelosuppressive chemotherapy and the mobilisation of peripheral blood progenitor cells in normal donors (allogeneic pbpc).

ניופוגן  MU 30 מזרק מוכן לשימוש ישראל - עברית - Ministry of Health

ניופוגן mu 30 מזרק מוכן לשימוש

amgen europe b.v. - filgrastim - תמיסה להזרקה - filgrastim 30 mu / 0.5 ml - filgrastim - filgrastim - - reduction in the duration and severity of neutropenia in patients treated with highly myelosuppressive chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes ).- reduction in the duration of neutropenia in patients undergoing high-dose cytotoxic chemotherapy followed by bone marrow transplantation. - in children or adults with severe congenital neutropenia cyclic neutropenia or idiopathic neutropenia a history of clinically important infections within the last 12 months and three documented episodes of neutropenia (with an anc< 5 x 1000000000) long-term administration of neupogen is indicated to increase neutrophil counts and to reduce infections. - neupogen is indicated for the mobilisation of autologous peripheral blood progenitor cells alone or following myelosuppressive chemotherapy and the mobilisation of peripheral blood progenitor cells in normal donors (allogeneic pbpc).

טבעגרסטים ישראל - עברית - Ministry of Health

טבעגרסטים

teva israel ltd - filgrastim - תמיסה להזרקה\אינפוזיה - filgrastim 0.6 mg/ml - filgrastim - filgrastim - tevagrastim is indicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes ) and for the reduction in the duration of neutropenia in patients undergoing myeloablative therapy followed by bone marrow transplantation considered to be at increased risk of prolonged severe neutropenia. the safety and efficacy of tevagrastim are similar in adults and children receiving cytotoxic chemotherapy. tevagrastim is indicated for the mobilisation of peripheral blood progenitor cells in normal donors (allogeneic pbpc). in patients children or adults with severe congenital neutropenia cyclic or idiopathic neutropenia with an absolute nuetrophil count (anc) less than or equal to 0.5 x 1000000000 /l and a history of severe or recurrent infections long term administration of tevagrastim is indicated to increase neutophil count and to red

לקסעדין ישראל - עברית - Ministry of Health

לקסעדין

teva israel ltd - bisacodyl - טבליות מצופות פילם - bisacodyl 5 mg - bisacodyl - bisacodyl - all types of constipation in ambulatory and bedridden in patients over the age of 6 years . preparation of patients for abdominal radiography and proctoscopy.

מוקסיפן   פורטה 250 מג אבקה להרחפה ישראל - עברית - Ministry of Health

מוקסיפן פורטה 250 מג אבקה להרחפה

abic marketing ltd, israel - amoxicillin as trihydrate - אבקה להכנת תרחיף - amoxicillin as trihydrate 250 mg / 5 ml - amoxicillin - amoxicillin - infections caused by amoxicillin - susceptible organisms and prevention of bacteremia in patients at risk of developing bacterial endocarditis.